UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...
The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...
UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN-102 ...
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved "The FDA acceptance of our NDA is a pivotal moment in our journey to bring UGN ...
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and ...
UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved PRINCETON, N.J., October 15, 2024--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to ...
(RTTNews) - UroGen Pharma Ltd. (URGN) said that the U.S. Food and Drug Administration accepted the New Drug Application or NDA for investigational drug UGN-102 (mitomycin) for intravesical solution.
UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback